Pricing

Tempest Therapeutics Inc (TPST)

followers ·
Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen R. Brady
Employees:
20
2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA, 94005
415-798-8589
    Formally known as:
  • OVASCIENCE INC COM (DE)
Stock Split History
DateRatio
2018-12-10 1:15
2021-06-28 1:15
Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available